Company Overview
Company Type: Private Company
Website: www.laurentpharma.com
Number of Employees: -
Year Founded: 2012
Total Amount Raised (CAD mm)†: 2.61
Total Rounds of Funding**:2
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Laurent Pharmaceuticals Inc., a biopharmaceutical company, develops orally-active drug candidates to modulate the immuno-inflammatory response in cystic fibrosis patients. It develops LAU-7b, a novel once-a-day oral form of fenretinide. The company was founded in 2012 and is based in Montreal, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Pislariu, Radu Cristian
CEO, President & Director
Radzioch, Danuta
Chief Scientific Adviser and Director
Colin, Patrick 
Chief Development Officer

Key Board Members
Name
Title
Rosconi, Yves 
Chairman of the Board
Pislariu, Radu Cristian
CEO, President & Director
Radzioch, Danuta
Chief Scientific Adviser and Director
Giese, Kevin A.
Director
Larose, Anne-Marie 
Director
LeBel, Marc 
Director
Mongrain, Francois 
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
1010 Sherbrooke St West Suite 2401 | Montreal, QC | H3A 2R7 | Canada
Phone: 514 513 2252   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Anges Québec
Sep-05-2018
Minority
-
Growth
Keiretsu Forum Mid-Atlantic LLC
Sep-05-2018
Minority
-
Growth
Cystic Fibrosis Canada, Endownment Arm
Mar-17-2016
Unknown
-
Venture
MSBi Valorisation Inc.
Mar-17-2016
Unknown
-
Venture
Keiretsu Capital LLC
-
Unknown
-
-


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-05-2018
May-29-2020
Private Placement
Target
Laurent Pharmaceuticals Inc.
Cystic Fibrosis Canada, Endownment Arm,MSBi Valorisation Inc.,Keiretsu Forum Mid-Atlantic LLC,Anges Québec,RSJ Private Equity Uzavreny Investicni Fond a.s. Buyer Funds:Anges Québec Capital Fund, Rsj Gradus

1.89
Mar-17-2016
Mar-17-2016
Private Placement
Target
Laurent Pharmaceuticals Inc.
Cystic Fibrosis Canada, Endownment Arm,MSBi Valorisation Inc.

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-29-2023
Product-Related Announcements
Laurent Pharmaceuticals Inc. Receives Health Canada's Approval to Initiate Phase 2/3 Clinical Trial in Long COVID
Nov-03-2022
Product-Related Announcements
Laurent Pharmaceuticals Presents Results from Phase 2 Clinical Study of LAU-7b in Cystic Fibrosis at the NACFC
Feb-15-2022
Product-Related Announcements
Laurent Pharmaceuticals Starts Phase 3 Study with Once-A-Day Oral Covid-19 Antiviral Treatment Candidate in Hospitalized Moderate-To-Severe Patients
Dec-15-2021
Product-Related Announcements
Laurent Pharmaceuticals Inc. Extends Covid-19 Phase 2 Study
Sep-30-2021
Product-Related Announcements
Laurent Pharmaceuticals Announces Topline Results from its Phase 2 RESOLUTION Clinical Trial of LAU-7b for the Treatment of COVID-19


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 28, 2023 06:18 AM
Laurent Pharmaceuticals Inc.
Laurent Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
23
GlobalData

Sep 14, 2023 09:30 PM
Laurent Pharmaceuticals Inc.
Laurent Pharmaceuticals Inc
Reports
56
GlobalData

Jun 28, 2023 04:17 AM
Laurent Pharmaceuticals Inc.
Laurent Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
23
GlobalData

Nov 24, 2022 04:10 AM
Laurent Pharmaceuticals Inc.
Laurent Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
27
GlobalData

Sep 21, 2022 07:53 AM
Laurent Pharmaceuticals Inc.
Laurent Pharmaceuticals Inc
Reports
53
GlobalData

Aug 25, 2022 08:01 AM
Laurent Pharmaceuticals Inc.
Laurent Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
20
GlobalData

Jun 15, 2022 04:10 AM
Laurent Pharmaceuticals Inc.
Laurent Pharmaceuticals Inc
Reports
53
GlobalData

May 23, 2022 04:28 AM
Laurent Pharmaceuticals Inc.
Laurent Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
20
GlobalData

Mar 15, 2022 04:57 AM
Laurent Pharmaceuticals Inc.
Laurent Pharmaceuticals Inc
Reports
53
GlobalData

Feb 24, 2022 05:56 AM
Laurent Pharmaceuticals Inc.
Laurent Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
20


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Rosconi, Yves 
Chairman of the Board
514 513 2252
-
-
Pislariu, Radu Cristian
CEO, President & Director
514 513 2252
-

Radzioch, Danuta
Chief Scientific Adviser and Director
514 513 2252
-
-
Giese, Kevin A.
Director
514 513 2252
-

Larose, Anne-Marie 
Director
514 982 2251 x400
-
amlarose@msbiv.com
LeBel, Marc 
Director
514-416-5659 (207)
-
marc.lebel@nuchemrx.com
Mongrain, Francois 
Independent Director
514 513 2252
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Pislariu, Radu Cristian
CEO, President & Director
514 513 2252
-

Radzioch, Danuta
Chief Scientific Adviser and Director
514 513 2252
-
-
Colin, Patrick 
Chief Development Officer
514 513 2252
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
